Close

BIO Opposes Brownback Amendment

Letter to Majority Leader Daschle

BIO's response to a two-year moratorium on cloning

In a letter to Sen. Orrin Hatch

BIO's comments regarding the NPRM that proposes changes to the HIPAA privacy regulation

Comments on Proposed Standards for Privacy of Individually Identifiable Health Information

Testimony of Charles A. Johnson, MBChB on behalf of the BIO before the Senate Committee on Health, Education, Labor and Pensions

Testimony of Michael J. Werner, Esq. before the Committee on Health, Education, Labor, and Pensions, hearing on Medical Privacy

Statement of J. Craig Venter, PhD, President, Celera Genomics

On Behalf of the Biotechnology Industry Organization Before the Subcommittee on Consumer Protection, U.S. House Committee on Energy and Commerce.

House Energy and Commerce Committee Testimony

By Thomas Okarma, CEO, Geron, Subcommittee on Health

Testimony of Thomas Okarma, PhD, MD President and CEO of Geron Corporation On Behalf of Biotechnology Industry Organization (BIO) Before the Subcommittee on Crime, House Judiciary Committee

By Thomas Okarma, CEO, Geron, Subcommittee on Crime

Testimony of Carl B. Feldbaum Before the Senate Commerce Committee Subcommittee on Science, Technology and Space

By Carl B. Feldbaum, President, BIO, Subcommittee on Science, Technology and Space

BIO comments on FDA proposed rule regarding disclosure of certain information in gene therapy and xenotransplantation experiments

he Biotechnology Industry Organization (BIO) is pleased to submit comments to the Food and Drug Administration (FDA) on the proposed rule "Availability for Public Disclosure and Submission to FDA for Public Disclosure of Certain Data and Information Related to Human Gene Therapy or Xenotransplantation." 66 Fed. Reg. 4688 (January 18, 2001) (the Proposed Rule or FDA’s Proposal).